Israeli and European scientists have identified a previously unknown molecular mechanism that helps explain why aging and neurological disease are often accompanied by sleep disturbances, mood disorders, and cognitive decline. This critical finding centres on the essential amino acid, tryptophan metabolism. For years, scientists understood that the balance of tryptophan’s metabolic pathways becomes disrupted in ageing brains and in neurodegenerative disorders. Consequently, this disruption contributes to impaired mood, learning, and sleep. Until now, the specific molecular cause of that imbalance remained a mystery.
SIRT6: The Metabolic Gatekeeper of the Brain
The research team, led by Prof. Debra Toiber, identified the enzyme sirtuin 6, or SIRT6, as the central regulator of this process. SIRT6 is widely recognised for its role in longevity. Moreover, this study demonstrates that SIRT6 also functions as an active gatekeeper of tryptophan utilisation. When SIRT6 activity is intact, tryptophan is properly distributed between two critical routes: the pathway that generates cellular energy, and the pathway that produces the essential neurotransmitters, serotonin and melatonin. These compounds are vital for neural stability, mood regulation, and sleep.
Disrupted Tryptophan Metabolism Fuels Neurotoxicity
A decline in SIRT6 activity is a hallmark of the ageing process. As SIRT6 activity drops, this metabolic balance shifts dramatically. Consequently, tryptophan is aggressively rerouted toward the kynurenine pathway. While this route supports energy production, it also generates byproducts that the researchers found to be toxic to nerve cells. Simultaneously, the production of protective serotonin and melatonin plummets. Professor Toiber stresses that this is not merely a passive decline. Instead, it is an active metabolic rerouting that directly damages the nervous system. Furthermore, multiple studies confirm that dysregulated tryptophan metabolism and its associated metabolites are implicated in a range of conditions, including Alzheimer’s, Huntington’s, and Parkinson’s diseases.
This research area is highly relevant to professionals seeking to understand the biological underpinnings of neurological disorders. Understanding these metabolic changes can guide therapeutic approaches, especially in managing complex conditions like dementia, which is covered in our specialised training programs. For those interested in advancing their knowledge in this field, consider exploring our Certification Course In Dementia.
TDO2 Inhibition: A Clear Therapeutic Opportunity
The scientists also demonstrated a path to reverse this damage. They inhibited a second enzyme, TDO2, in fruit fly models lacking SIRT6. TDO2 plays a key role in pushing tryptophan into the toxic kynurenine pathway. Blocking TDO2 significantly prevented neuromotor deterioration and reduced pathological changes in brain tissue, pointing to a clear therapeutic opportunity. Prof. Toiber states that this research positions the SIRT6 enzyme as a critical and primary drug target to combat degenerative brain pathology. Future therapies could therefore aim to correct this underlying metabolic imbalance through compounds that enhance SIRT6 activity or selectively inhibit TDO2.
Developing targeted therapies for neurodegenerative pathology requires deep knowledge in neurology and associated sciences. Clinicians aiming to specialise in brain health can enhance their expertise through courses focusing on the nervous system, such as our offerings in Neurology Speciality Courses.
Compounds that inhibit TDO2 have already been investigated in other medical fields, including cancer and immunology. Therefore, repurposing existing compounds could significantly shorten development timelines compared to starting entirely new drug discovery programs. Beyond treatment, alterations in tryptophan metabolites or reduced SIRT6 activity may serve as detectable biomarkers in blood or cerebrospinal fluid. Clinicians could use these biomarkers for earlier diagnosis, allowing them to identify individuals at risk of cognitive decline, mood disorders, or sleep disturbances before symptoms become severe.
Frequently Asked Questions
Q1: What is the role of the SIRT6 enzyme in brain health?
The SIRT6 enzyme acts as a central metabolic switch for the essential amino acid tryptophan. It regulates the balance of tryptophan’s utilisation between pathways that produce energy and those that produce essential neurotransmitters like serotonin and melatonin.
Q2: How is the kynurenine pathway related to neurodegenerative disease?
The kynurenine pathway is a metabolic route for tryptophan that increases with age and declining SIRT6 activity. This pathway produces byproducts that are neurotoxic, while simultaneously depleting the brain’s supply of protective serotonin and melatonin. This imbalance is closely linked to neurodegeneration.
Q3: What is the significance of TDO2 inhibition in this context?
TDO2 is an enzyme that drives tryptophan into the toxic kynurenine pathway. Inhibiting TDO2 successfully redirected tryptophan away from the toxic route in model organisms. This action prevented neurodegeneration and is considered a promising drug target for reversing the pathology.
For those interested in understanding or treating conditions impacting the central nervous system, advanced study in areas like stroke medicine or general neurology is beneficial. Professionals aiming to deepen their knowledge in specific neuro-related diseases might find our Certification Course In Stroke Medicine directly applicable to understanding pathological mechanisms.
References
- Brain enzyme discovery may open new path to treat neurodegenerative disease – ETHealthworld
- Changes in brain tryptophan metabolism elicited by ageing, social environment, and psychological stress in mice. Physiology & Behaviour. 2012.
- SIRT6 regulates Tryptophan catabolism, preventing metabolite imbalance and neurodegeneration. ResearchGate. 2024.
- Tryptophan Metabolism and Neurodegeneration: Longitudinal Associations of Kynurenine Pathway Metabolites with Cognitive Performance and Plasma ADRD Biomarkers in the Duke Physical Performance Across the LifeSpan Study. PubMed Central. 2023.
- Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. University of Leicester Research Repository. 2016.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.